Results 231 to 240 of about 26,895 (263)
Some of the next articles are maybe not open access.
Nihon rinsho. Japanese journal of clinical medicine, 2016
SGLT2 is a glucose transporter which plays an important role for reabsorption of urinary glucose depending on the sodium concentration gradient. SGLT2 is mainly present in apical site of S1 segment of renal proximal tubule and accounts for approximately 90% of total urinary glucose reabsorption. SLC5a2, which codes SGLT2, is also known as the causative
Naoto, Kubota, Takashi, Kadowaki
openaire +1 more source
SGLT2 is a glucose transporter which plays an important role for reabsorption of urinary glucose depending on the sodium concentration gradient. SGLT2 is mainly present in apical site of S1 segment of renal proximal tubule and accounts for approximately 90% of total urinary glucose reabsorption. SLC5a2, which codes SGLT2, is also known as the causative
Naoto, Kubota, Takashi, Kadowaki
openaire +1 more source
SGLT2 inhibitors: are they safe?
Postgraduate Medicine, 2017Sodium-glucose linked transporter type 2 (SGLT2) inhibitors are a relatively new class of antidiabetic drugs with positive cardiovascular and kidney effects. The aim of this review is to present the safety issues associated with SGLT2 inhibitors. Urogenital infections are the most frequently encountered adverse events, although tend to be mild to ...
Sebastian Filippas-Ntekouan +2 more
openaire +2 more sources
An update on the safety of SGLT2 inhibitors
Expert Opinion on Drug Safety, 2019Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are recommended after metformin for a large spectrum of patients with type 2 diabetes, because of a favorable benefit/risk profile despite a variety of adverse events.This narrative review discusses the safety profile of SGLT2is: initial concerns (cardiovascular safety, acute renal failure ...
openaire +2 more sources
Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin
Chemico-Biological Interactions, 2014The carcinogenicity potential of canagliflozin, an inhibitor of SGLT2, was evaluated in a 2-year rat study (10, 30, and 100 mg/kg). Rats showed an increase in pheochromocytomas, renal tubular tumors, and testicular Leydig cell tumors. Systemic exposure multiples at the highest dose relative to the maximum clinical dose were 12- to 21-fold ...
Sandra, De Jonghe +8 more
openaire +2 more sources
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials
Clinical Cardiology, 2021David Z I Cherney +2 more
exaly
Hereditary renal glycosuria, diabetes and responses to SGLT2 inhibitor
Journal of Diabetes, 2022Qian Ren, Siqian Gong, Linong Ji
exaly
Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor
Bioorganic and Medicinal Chemistry, 2021Kazuo Shimizu +2 more
exaly